Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development

(NASDAQ: OVID) Ovid Therapeutics Inc. announced several strategic appointments to its executive leadership team, including Kevin Norrett as Chief Business Officer, Charles Carter as Chief Financial Officer, Eliseo Salinas as Executive R&D Advisor, and Victoria Fort as Chief Strategy Officer. Charles Carter succeeds Jeffrey Rona, who will remain a long-term advisor to the Company through 2027 to ensure a smooth operational transition. Victoria Fort led two successful financing rounds that extended Ovid’s cash runway into 2029. Ovid is developing OV329, a next-generation GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant focal onset seizures (FOS) and developmental and epileptic encephalopathies (DEEs), including tuberous sclerosis complex (TSC) associated seizures and infantile spasms (IS). The company is also developing OV4071 and other compounds that directly activate the KCC2 transporter for multiple CNS disorders. Ovid Therapeutics Inc. is a New York-based biopharmaceutical company dedicated to pioneering better, gentler medicines for the brain. The company projects that the new appointments will support its next phase of development and accelerate the characterization and value creation of its programs.